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bjectives We sought to evaluate the impact of a strategy of reduced-dose ﬁbrinolytic acceleration
f ST-segment elevation myocardial infarction (STEMI) treatment followed by urgent percutaneous
oronary intervention (FAST-PCI) on the mortality, reinfarction, and stroke rates in STEMI patients as
ompared with a primary percutaneous coronary intervention (PPCI) approach.
ackground Time to reperfusion is a major determinant of mortality among STEMI patients. Rapid
nitiation of ﬁbrinolytic therapy can shorten time to reperfusion, and mechanical therapy of the cul-
rit lesion is known to be beneﬁcial.
ethods Data from 2,869 STEMI patients treated in 5 high-volume percutaneous coronary interven-
ion (PCI) centers were pooled for analysis. Mortality at 30 days was the primary end point. Death,
einfarction, and stroke were secondary end points, as were infarct-related artery TIMI (Thrombolysis
n Myocardial Infarction) ﬂow grade before PCI and shock on arrival to the catheterization laboratory.
esults Compared to PPCI, mortality at 30 days was signiﬁcantly lower with FAST-PCI (3.8% vs. 6.4%,
 0.002). The combined triple end point of death, reinfarction, or stroke was also less frequent (5.1%
s. 8.9%, p  0.0001). The FAST-PCI patients had a lower incidence of Killip class IV (5.6% vs. 10.9%, p 
.0001) and higher infarct-related artery TIMI ﬂow grades (2.1  1.2 vs. 1.1  1.3, p  0.0001) upon ar-
ival in the catheterization laboratory. Stepwise logistic regression analysis demonstrated that FAST-PCI
as an independent predictor of 30-day mortality (relative risk  0.542, p  0.0151).
onclusions The FAST-PCI strategy reduced the mortality and combined end point of death, rein-
arction, and stroke among STEMI patients, without increasing the risk of stroke or bleeding, com-
ared to PPCI. Fibrinolysis before hospital admission also increased the initial infarct-related artery
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505espite advances in medications and interventional tech-
iques, ST-segment elevation myocardial infarction
STEMI) remains a major cause of mortality in the U.S.
ata from 3,377 hospitals nationwide show that the short-
erm (in-hospital) mortality is 8% among STEMI patients
1). Recent data also show that the mean time to percuta-
eous coronary intervention (PCI) is 253 min, and the mean
ime to hospital-administered fibrinolysis is 54 min (1). In a
ecent assessment of hospitals for adherence to national
uideline recommendations, only 35% of hospitals were able
o achieve door-to-balloon times within the recommended
0 min, and there has not been any real improvement in the
oor-to-balloon time in the nation during the last decade
2). Reducing the time from symptom onset to reperfusion
the ischemic time) is the major determinant for reducing
-year mortality (3). In contemporary registries, mortality
oubles as door-to-balloon time exceeds 2 h (4,5).
The current, widely accepted use of primary percutaneous
oronary intervention (PPCI) or hospital-administered fi-
rinolytic therapy will not be sufficient to decrease the total
schemic time to 2 h. The use of a strategy of fibrinolytic
cceleration of STEMI treatment coupled with urgent
ercutaneous coronary intervention (FAST-PCI) in which
TEMI patients are identified and treated with reduced-
ose fibrinolytic agents in the field or at STEMI referral
ospitals, and then transported to the closest STEMI
eceiving center for urgent PCI, may offer an effective
olution to the problem. Previous trials have demonstrated a
ecrease in mortality with pre-hospital fibrinolysis (6,7).
onversely, in a recent meta-analysis of facilitated PCI
ersus primary PCI in STEMI, Keeley at al. (8) concluded
hat facilitated PCI (fibrinolytic agents or glycoprotein
Ib/IIIa inhibitors, administered just before or after hospital
rrival) increased mortality and nonfatal myocardial infarc-
ion as well as risks of bleeding and stroke. This meta-
nalysis analyzed all the randomized trials regardless of the
acilitator drug used, but the analysis was mainly driven by
he ASSENT-4 (Assessment of the Safety and Efficacy of a
ew Treatment Strategy with Percutaneous Coronary In-
ervention for Acute Myocardial Infarction) trial (9). The
SSENT-4 trial compared PPCI to full-dose tenecteplase
herapy before PCI for patients with STEMI. It was not
esigned to significantly shorten the ischemic time. The
rial was stopped early because of increased mortality in
he facilitated PCI arm, largely driven by an excess of
troke deaths.
There remains a need to better determine the impact of
uch shorter ischemic times than are achievable with
urrently practiced reperfusion strategies. We evaluated the
mpact of true pre-hospital administration of half-dose
brinolytic therapy coupled with FAST-PCI on the mor-
ality, reinfarction, and stroke rates among STEMI patients
s compared with patients administered PPCI without
brinolytic acceleration. aethods
he 5 centers of the AMICO (Alliance for Myocardial
nfarction Care Optimization) registry include the Minne-
polis Heart Institute at Abbott Northwestern Hospital
T.D.H., D.M.L.) (10,11), Dartmouth Hitchcock Medical
enter (M.S., N.W.N.), Leipzig Heart Center (H.T., G.S.)
12), Hartford Hospital (R.G.M.), and the University of
exas at Houston/Memorial Hermann Hospital (R.W.S.,
.V.A., S.S., A.E.D.) (13,14). Data from their respective
egistries were obtained and merged into a master database.
ach center received approval from their respective Institu-
ional Review Boards for their protocols.
tudy subjects. The definition of an eligible patient for
nclusion varied slightly at each center but used conventional
riteria of ST-segment elevation of 1 mm in 2 contiguous
eads, and no obvious contraindications for fibrinolysis.
emographic, clinical, procedural, and outcome data
ere tabulated. There were
,200 patients in the FAST-PCI
roup and 1,669 patients in the
PCI group. The types of fi-
rinolytic agents used were rete-
lase (52.8%), tenecteplase
39.4%), tissue-type plasmino-
en activator (2.5%), or unspec-
fied (5.25%). The fibrinolytic
gents were either administered
n the field, during transfer, or at
he transferring hospital, and not
t the PCI center. The selection
riteria for PPCI versus FAST-
CI in each center as well as
he number of patients from
ach center are summarized in
able 1.
djunctive agents. Local protocols dictated the use of
spirin, heparin, or low molecular weight heparin and
lopidogrel in the field or at the transferring hospital for all
atients.
nd points. The primary end point for analysis was mortal-
ty at 30 days. The major secondary end point (at 30 days,
xcept for Dartmouth Hitchcock Medical Center data,
hich had only in-hospital data for recurrent myocardial
nfarction [re-MI] and stroke rates) was the combination of
eath, re-MI, and stroke. Culprit artery Thrombolysis In
yocardial Infarction (TIMI) flow grade and Killip class IV
shock) on arrival, as well as the peak creatine kinase levels
ere pre-specified analytic end points.
ata analysis and statistical methods. Categorical variables
re expressed as number and percentage of patients, and
ere tested for differences using the chi-square tests. Con-
inuous variables are expressed as mean and standard devi-
Abbreviations
and Acronyms
FAST-PCI  urgent
percutaneous coronary
intervention
PCI  percutaneous
coronary intervention
PPCI  primary
percutaneous coronary
intervention
Re-MI  recurrent
myocardial infarction
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctiontion, and were tested for differences using Student t test.
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506ge, creatinine, hyperlipidemia, diabetes mellitus, gender,
ypertension, smoking, and centers were entered as candi-
ate independent variables for stepwise logistic regression
nalyses. Stepwise logistic regression was used to identify
ndependent prognostic factors for 30-day death, stroke,
I, and the combination of these events. Stepwise logistic
egression was done to identify predictors for decreased peak
reatine kinase.
esults
here were 2,869 patients registered at the 5 different sites
etween 2001 and 2006. Of these, 1,200 were treated by
AST-PCI, receiving pre-hospital half-dose fibrinolysis
oupled by immediate coronary angiography and PCI if
ppropriate. The remaining 1,669 were treated with PPCI
lone.
emographics. The demographics of the patient groups
ere representative of typical STEMI patient populations
Table 2). Importantly, patients with pre-hospital cardiac
rrest and shock were not excluded. Patients undergoing
brinolysis before hospital admission were slightly younger,
ith less frequent history of coronary artery bypass graft
urgery and hypertension, and more of them were current
mokers and had a history of hyperlipidemia. The groups
ere well matched in the number of prior MIs, prior PCIs,
nd the presence of diabetes mellitus. The baseline creati-
ine was 0.1 mg/dl higher in the group without pre-hospital
brinolysis, but both groups had a normal baseline creati-
ine value.
ime to reperfusion. We were unable to determine the true
ymptom onset to reperfusion times in all of our patients.
he initial medical contact to balloon time was used instead
s a surrogate of time to reperfusion. The PPCI group had
horter initial medical contact to balloon times (168  318
in in the PPCI group vs. 196  263 min in the
AST-PCI group, p 0.012). Median times were 110 min
or the PPCI and 138 min for the FAST-PCI groups.
indings on presentation to the STEMI center. The mean
IMI flow grade before the intervention was significantly
igher in the FAST-PCI group of patients (2.1  1.2 vs.
Table 1. Selection Criteria and Contribution of Patients From Each Center
Center Selection Criteria
DHMC By geographic location and intended strategy with cath
Hartford By geographical location of the patient
Houston MHH/HVI Randomized PATCAR study (14)
Leipzig Randomized study of FAST-PCI and PPCI patients from
Minneapolis By geographical location of the patient (11)
DHMC  Dartmouth Hitchcock Medical Center; FAST-PCI  fibrinolytic acceleration of ST-segm
MHH/HVI  Memorial Hermann Hospital Heart and Vascular Institute; PATCAR  Prehospital A
percutaneous coronary intervention..1  1.3, p  0.0001) compared with the PPCI patients.significantly lower percentage of patients in the FAST-
CI group were in cardiogenic shock at presentation to the
CI hospital (5.6% vs. 10.9%, p  0.0001) (Table 2). The
otal number of vessels diseased was 1.66  0.84 in the
AST-PCI group and 1.59 0.80 in the PPCI group (p
.097). (Data were available for 924 FAST-PCI and 1,336
PCI patients). The left ventricular ejection fraction of the
PCI patients (n  1,148) was slightly lower than that of
he FAST-PCI patients (n  754; 45.5  12% vs. 46.5 
1%, p  0.019).
afety. The TIMI major bleeding rates between the two
roups were slightly in favor of the FAST-PCI group: the
PCI group with a 6.53% and the FAST-PCI group with
#) FAST-PCI (n) PPCI (n)
ation laboratory enrollment 250 100
544 1,040
55 72
ates not included in the study (11,12) 80 135
271 322
ation myocardial infarction treatment followed by urgent percutaneous coronary intervention;
tration of Thrombolytic Therapy with Urgent Culprit Artery Revascularization; PPCI  primary
Table 2. Baseline Characteristics of Patients Treated With and Without
Pre-Hospital Fibrinolytic Therapy and Hospital Presentation and Course
Variables
FAST-PCI
(n  1,200)
PPCI
(n  1,669) p Value
Baseline characteristics
Age (yrs) 61 12 63 14 0.0001*
Women 323 (27%) 524 (31%) 0.010
Prior PCI 109 (11%) 216 (14%) 0.093
Prior MI 162 (14%) 235 (14%) 0.672
Prior CABG 47 (4%) 113 (7%) 0.001
Hypertension 629 (53%) 963 (58%) 0.010
Smoking 554 (47%) 607 (37%) 0.0001
Hyperlipidemia 620 (54%) 837 (51%) 0.089
Diabetes mellitus 223 (19%) 352 (21%) 0.108
Creatinine 1.0 0.5 1.1 0.8 0.005*
Cardiovascular disease 33 (4%) 76 (6%) 0.024
Family history 405 (43%) 503 (36%) 0.0004
Hospital presentation and course
Killip class IV 5.6% 10.9% 0.0001
TIMI pre-PCI 2.1 1.2 1.1 1.3 0.0001†
Peak creatine kinase 1,299 1,957 1,667 2,247 0.0001*
Intra-aortic balloon time 195.8 262.8 168.1 317.6 0.012
Glycoprotein IIb/IIIa use 57.6% 35.8% 0.0001
Values are mean SD or n (%). *p Value based on Student t test; all others based on chi-square
test. †p Value based on Wilcoxon rank-sum test.
CABG  coronary artery bypass graft surgery; FAST-PCI  fibrinolytic acceleration of ST-
segment elevation myocardial infarction treatment followed by urgent percutaneous coronary
intervention; MI  myocardial infarction; PCI  percutaneous coronary intervention; TIMI (Ref.
eteriz
same d
ent elev
dminisThrombolysis In Myocardial Infarction.
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5074.75% major bleeding rate (p  0.044). There was no
ncrease in the stroke rate (ischemic and hemorrhagic) in the
AST-PCI group compared with the PPCI group (1.4% vs.
.1%, p  NS). The total number of intracranial hemor-
hages was 7 of 1,200 (0.58%) in the FAST-PCI group and
of 1,669 (0.24%) in the PPCI group (p  0.08).
rimary end points. The frequencies of death, re-MI, or
ew stroke among patients treated with and without
educed-dose pre-hospital fibrinolytic agents are given in
able 3 and Figure 1. There were fewer deaths, less
einfarction, and a lower combined end point with the
trategy of using reduced-dose pre-hospital fibrinolysis.
ultivariate analysis. Pre-hospital reduced-dose fibrinolytic
se was a significant independent predictor for 30-day
urvival after controlling the confounding effect of age,
reatinine level, hyperlipidemia, and diabetes mellitus, with
46% lower chance of death at 30 days compared with
atients who were treated with PPCI. (Table 4).
Diabetes mellitus (p  0.008) was the only significant
ndependent prognostic factor for 30-day stroke. Previous
ardiovascular disease (p  0.019) was the only significant
ndependent prognostic factor for 30-day re-MI.
Pre-hospital fibrinolysis was not a significant indepen-
ent predictor for absence of any event (death, stroke, or
e-MI) after controlling the confounding effect of age,
reatinine, hyperlipidemia, and diabetes mellitus (Table 4).
re-hospital fibrinolysis was a significant negative indepen-
ent predictor for peak creatine kinase after controlling the
onfounding effects of age, creatinine, prior MI, and family
istory (Table 4).
iscussion
urrent mortality among STEMI patients across the U.S. is
pproximately 8% or higher (1). Early treatment with either
brinolysis (15) or primary PCI (3) is associated with a
ecrease in mortality that is correlated with reduced isch-
mic time. In an analysis of the National Registry of
yocardial Infarction database from 1992 to 2002, Mc-
amara et al. (2) showed that fewer than one-half of the
atients with STEMI receive reperfusion therapy within the
ublished guidelines time frame, and there was no signifi-
Table 3. 30-Day Outcomes
Variable
FAST-PCI
(n  1,200)
PPCI
(n  1,669) p Value* p Value†
Death 3.8% 6.4% 0.002 0.002
Stroke 1.4% 1.1% 0.416 0.808
Recurrent MI 0.8% 1.9% 0.013 0.0005
Any event‡ 5.1% 8.9% 0.0001 0.0001
*p Value based on chi-square test. †p Value based onMantel-Haenszel test, controlling the effect
of institutions. ‡Occurrence of any death, stroke, or MI (Dartmouth Hitchcock Medical
Center provided in-hospital stroke and recurrent MI data).PPCI primary percutaneous coronary intervention; other abbreviations as in Table 2.ant improvement in the mean time to reperfusion over the
ears. Boersma et al. (15) analyzed more than 50,000
atients receiving fibrinolytics for STEMI, in published
rials that enrolled more than 100 patients between 1983
nd 1993. They examined the proportional gain in mortality
eduction with very early treatment (15). Their analysis
uggested that with early treatment within 1 h of onset of
ymptoms, an additional 60 lives might be saved per 1,000
atients treated.
Figure 1. Univariate Analysis of Death, Recurrent Myocardial Infarction,
Stroke, and Combined End Points With FAST-PCI Compared to PPCI
FAST-PCI  ﬁbrinolytic acceleration of ST-segment elevation myocardial
infarction treatment coupled with urgent percutaneous coronary interven-
tion; PPCI  primary percutaneous coronary intervention; re-MI  recurrent
myocardial infarction.
Table 4. Predictors of 30-Day Mortality, 30-Day Major Adverse Events,
and Decreased Peak Creatine Kinase
Variable RR 95% CI p Value
Predictors of 30-day mortality
Age 1.054 1.037–1.071 0.0001
Serum creatinine 1.563 1.349–1.812 0.0001
Hyperlipidemia 0.398 0.258–0.613 0.0001
Diabetes mellitus 2.063 1.332–3.196 0.0012
Pre-hospital ﬁbrinolysis 0.542 0.331–0.888 0.0151
Predictors of 30-day major adverse events*
Age 1.051 1.036–1.066 0.0001
Serum creatinine 1.481 1.287–1.705 0.0001
Hyperlipidemia 0.495 0.342–0.717 0.0002
Diabetes mellitus 2.109 1.430–3.109 0.0002
Predictors of decreased peak creatine kinase
Age 1.054 1.035–1.073 0.0001
Serum creatinine 1.514 1.286–1.782 0.0001
Hyperlipidemia 0.402 0.249–0.648 0.0002
Diabetes mellitus 2.341 1.457–3.762 0.0004
Pre-hospital ﬁbrinolysis 0.536 0.315–0.913 0.0217
*Death, recurrent myocardial infarction, and stroke.CI confidence interval; RR relative risk.
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508Infarct-related artery patency at presentation to the car-
iac catheterization laboratory has been associated with
etter outcomes (16). Among 2,507 patients enrolled in 4
AMI (Primary Angioplasty in Myocardial Infarction)
rials undergoing PPCI for STEMI, patients who had
IMI flow grade 3 at presentation compared with patients
ho did not have TIMI flow grade 3 had better left
entricular ejection fraction (57  10% vs. 53  11%, p 
.003) and were less likely to be in heart failure (7.0% vs.
1.6%, p  0.009). Patients with initial TIMI flow grade 3
ad significantly lower in-hospital rates of mortality, new-
nset heart failure, and hypotension, and had a shorter
ospital stay. Cumulative 6-month mortality was 0.5% in
atients with initial TIMI flow grade 3, 2.8% with TIMI
ow grade 2, and 4.4% with initial TIMI flow grade 0/1 (p
0.009). By multivariate analysis, TIMI flow grade 3
efore PCI was an independent determinant of survival
odds ratio: 2.1, p  0.04), even when corrected for by
ost-procedural TIMI flow grade 3.
The use of fibrinolysis has been associated with a TIMI
ow grade 3 rate of 32% to 54% (17) compared to a rate of
0% to 97% with PPCI (18). Fibrinolysis alone has also
een associated with reocclusion (19), and this has been a
ajor factor in the better outcomes with PPCI in STEMI
rials compared to fibrinolysis.
We have recently demonstrated a reduced incidence of
re-hospital shock, improved infarct-related artery initial
atency, and reduced ischemic time with pre-hospital,
educed-dose fibrinolysis coupled with urgent PCI com-
ared with either pre-hospital fibrinolysis alone or PPCI
14). In the present study, with the combination of pre-
ospital, reduced-dose fibrinolysis and pre-hospital notifi-
ation of the cardiac catheterization team, the 30-day
ortality of STEMI patients has been reduced by half with
o increase in major bleeding complications.
Although the overall results were negative for facilitated
CI with full-dose fibrinolysis in the ASSENT-4 study,
atients in that trial who received fibrinolysis in the ambu-
ance had better outcomes (9). In the MITI (Myocardial
nfarction Triage and Intervention) trial, the patients
reated “very early” (within 70 min of symptom onset) with
re-hospital fibrinolysis had lower mortality (1.2% vs. 8.7%)
nd smaller infarct size (20). In a meta-analysis of pre-
ospital fibrinolysis, it was shown that the time to reperfu-
ion treatment was almost an hour shorter with pre-hospital
dministration than for the patients with in-hospital treat-
ent, and all-cause mortality was significantly reduced (7).
urrently, even in the best centers with the use of standard
rder sets for fibrinolytic agents or PPCI, a single phone call
ystem, a central communication system for fast transfers
nd bypassing emergency department evaluation, the in-
ospital mortality of patients with STEMI who had PPCI
as 5.7% to 6.6% and the 30-day mortality was 7.1% to
.2% (21). pAlthough PPCI as reperfusion therapy for STEMI is
uperior to fibrinolysis alone (18), the more widespread use
f this mode of therapy is limited by the unavailability of
rimary angioplasty centers. With the widespread availabil-
ty of fibrinolytic agents and the durability of PPCI for
TEMI, it has been suggested that perhaps the combina-
ion of these two therapies might be the optimal treatment
22). The recently published ASSENT-4 PCI trial tried to
ddress this issue. However, the use of glycoprotein IIb/IIIa
nhibitors was not permitted in the facilitated PCI group
xcept for bailout situations, and the use of clopidogrel was
imited to the stented patients at the time of cardiac
atheterization (9). Nevertheless, this trial showed that
ull-dose tenecteplase given 1 to 3 h before PCI for STEMI
as associated with worse outcomes despite having higher
nfarct-related artery patency rates at presentation to the
ardiac catheterization laboratory. There were 8 deaths from
troke in the fibrinolytic arm (and none in the PCI arm),
ith a total stroke rate of 1.8%. This is similar to the stroke
ate reported in ASSENT-3 with the same fibrinolytic
gent *23).
In the ASSENT-4 PCI trial, the patients with TIMI
ow grades 0 to 2 before PCI in the facilitated PCI group
ere less likely to have TIMI flow grade 3 after the PCI.
his finding might be attributed to the prothrombotic
nvironment after fibrinolytic therapy as well as to the
uboptimal antithrombin therapy in this trial (24). The
ajor differences between the ASSENT-4 PCI trial and our
tudy include the reduced dose of fibrinolytic agent, shorter
ymptom onset to treatment times, and upstream use of
ntiplatelet agents. Although this was not a randomized
linical trial, in this multicenter cohort of STEMI patients,
e have demonstrated that reduced-dose fibrinolysis fol-
owed by urgent routine PCI reduces 30-day mortality, the
ombined end points of death, re-MI, and stroke, and also
educes peak creatine kinase and the incidence of shock at
resentation, compared to a primary PCI strategy. The
afety of this approach was also demonstrated by no increase
n intracranial or major bleeding despite more frequent use
f glycoprotein IIb/IIIa inhibitors in the FAST-PCI group.
Recently, the similarly sized and randomized FINESSE
Facilitated Intervention With Enhanced Reperfusion
peed to Stop Events) study was presented (25,26). In this
rial, 2,452 patients with STEMI presenting less than 6 h
fter symptom onset, with 1 to 4 h estimated time to
atheterization, were randomly assigned to in-hospital half-
ose reteplase (patients 75 years of age) followed by PCI,
r in-hospital abciximab bolus followed by PCI, or in-
aboratory abciximab and PCI. When compared to our
resent study, the FINESSE trial did not use clopidogrel
oading preintervention by protocol and used a double bolus
5-U 5-U) fibrinolytic agent for most of the patients. The
se of an abciximab bolus was also mandated by the
rotocol. Furthermore, the median time to balloon was
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509.2 h in all patients, and the symptom onset to first bolus of
eteplase was 165 min. Only 60% of the FINESSE patients
ere treated within 3 h of symptom onset, and of those who
ere treated within 3 h, there was a trend toward more
linical benefit with reteplase and abciximab combination
reatment. None of the patients had pre-hospital adminis-
ration of half-dose fibrinolysis, whereas all of our FAST-
CI patients did. The FINESSE study showed that the
n-hospital administration of half-dose double bolus rete-
lase with abciximab bolus before urgent PCI in non–low-
isk patients (inferior MI and 60 years of age) with
TEMI did not have an additional benefit over primary
CI. Furthermore, the risk of nonintracranial TIMI major/
inor bleeding was increased with the reteplase and abcix-
mab combination approach, when compared to the primary
CI group (14.5% vs. 6.9%, respectively). Although isch-
mic stroke occurred in 0.5% of the patients in the facili-
ated groups of the FINESSE trial and in 0.9% of the
atients in the primary PCI group, the intracranial hemor-
hage rates were higher in the reteplase and abciximab
ombination group than in the PPCI group (0.6% vs. 0.1%).
t is an intriguing finding in this trial, however, that none of
he patients 75 years of age had an intracranial hemor-
hage. Those patients received a single bolus of reteplase,
hich was similar in pattern but half the dose of our
egimen.
tudy limitations. This study was not randomized between
he reduced-dose fibrinolytic acceleration of STEMI treat-
ent coupled with urgent PCI, and primary PCI. Because
f the nonrandomized nature of this study, there were some
ontrivial differences in the baseline characteristics of the
atients. There was no uniform study protocol, which would
ave provided a uniform definition of ischemic time (time
rom onset of symptoms to reperfusion) between the centers
articipating in the analysis. The patients in the 2 groups
ere treated in the same hospitals by the same physicians
nd the door-to-balloon times were not different between
he groups, but there was a trend toward longer balloon
imes in the FAST-PCI group.
onclusions
ur results show that it is feasible, safe, and effective to use
pre-hospital (before transfer), reduced-dose fibrinolytic
gent coupled with effective antithrombotic treatment, fol-
owed by PCI for STEMI. These results with reduced-dose
brinolytic acceleration of STEMI treatment coupled with
rgent PCI further emphasize the need for an appropriately
owered, randomized trial to test the hypothesis that this
trategy will be more effective than PPCI alone for STEMI.
t is possible that this strategy could further reduce STEMI-
ssociated mortality.cknowledgment
he authors thank Mary T. Vooletich, RN, for her help in
he coordination of this study.
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